CITIUS PHARMAC (Germany) Buy Hold or Sell Recommendation
| 47N Stock | EUR 3.29 0.00 0.00% |
Assuming the 90 days horizon and complete risk avoidance on your part, our recommendation regarding CITIUS PHARMAC DL is 'Strong Sell'. Macroaxis provides CITIUS PHARMAC buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding 47N positions.
Check out CITIUS PHARMAC Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as CITIUS and provide practical buy, sell, or hold advice based on investors' constraints. CITIUS PHARMAC DL. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
CITIUS |
Execute CITIUS PHARMAC Buy or Sell Advice
The CITIUS recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on CITIUS PHARMAC DL. Macroaxis does not own or have any residual interests in CITIUS PHARMAC DL or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute CITIUS PHARMAC's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
CITIUS PHARMAC Trading Alerts and Improvement Suggestions
| CITIUS PHARMAC DL generated a negative expected return over the last 90 days | |
| CITIUS PHARMAC DL has high historical volatility and very poor performance | |
| CITIUS PHARMAC DL has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (23.66 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| CITIUS PHARMAC DL has accumulated about 115.66 M in cash with (22.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.79. |
CITIUS PHARMAC Returns Distribution Density
The distribution of CITIUS PHARMAC's historical returns is an attempt to chart the uncertainty of CITIUS PHARMAC's future price movements. The chart of the probability distribution of CITIUS PHARMAC daily returns describes the distribution of returns around its average expected value. We use CITIUS PHARMAC DL price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of CITIUS PHARMAC returns is essential to provide solid investment advice for CITIUS PHARMAC.
| Mean Return | -1.56 | Value At Risk | -13.65 | Potential Upside | 9.69 | Standard Deviation | 7.77 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of CITIUS PHARMAC historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
CITIUS PHARMAC Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to CITIUS PHARMAC or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that CITIUS PHARMAC's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a CITIUS stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -1.57 | |
β | Beta against Dow Jones | 0.07 | |
σ | Overall volatility | 7.83 | |
Ir | Information ratio | -0.21 |
CITIUS PHARMAC Volatility Alert
CITIUS PHARMAC DL is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure CITIUS PHARMAC's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact CITIUS PHARMAC's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.CITIUS PHARMAC Fundamentals Vs Peers
Comparing CITIUS PHARMAC's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze CITIUS PHARMAC's direct or indirect competition across all of the common fundamentals between CITIUS PHARMAC and the related equities. This way, we can detect undervalued stocks with similar characteristics as CITIUS PHARMAC or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of CITIUS PHARMAC's fundamental indicators could also be used in its relative valuation, which is a method of valuing CITIUS PHARMAC by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare CITIUS PHARMAC to competition |
| Fundamentals | CITIUS PHARMAC | Peer Average |
| Return On Equity | -0.28 | -0.31 |
| Return On Asset | -0.16 | -0.14 |
| Shares Outstanding | 146.21 M | 571.82 M |
| Shares Owned By Insiders | 8.42 % | 10.09 % |
| Shares Owned By Institutions | 11.00 % | 39.21 % |
| EBITDA | (33.31 M) | 3.9 B |
| Net Income | (23.66 M) | 570.98 M |
| Cash And Equivalents | 115.66 M | 2.7 B |
| Cash Per Share | 0.79 X | 5.01 X |
| Total Debt | 1.06 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 32.48 X | 2.16 X |
| Book Value Per Share | 0.70 X | 1.93 K |
| Cash Flow From Operations | (22.02 M) | 971.22 M |
| Earnings Per Share | (0.19) X | 3.12 X |
| Target Price | 7.0 | |
| Number Of Employees | 21 | 18.84 K |
| Beta | 1.2 | -0.15 |
| Market Capitalization | 186.2 M | 19.03 B |
CITIUS PHARMAC Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as CITIUS . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About CITIUS PHARMAC Buy or Sell Advice
When is the right time to buy or sell CITIUS PHARMAC DL? Buying financial instruments such as CITIUS Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having CITIUS PHARMAC in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Artificial Intelligence Thematic Idea Now
Artificial Intelligence
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in CITIUS Stock
CITIUS PHARMAC financial ratios help investors to determine whether CITIUS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CITIUS with respect to the benefits of owning CITIUS PHARMAC security.